Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirk E Evoy

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Frontiers in Public Health|September 4, 2024
Editorial: Reviews in opioid use disordersWendy Walwyn, Kirk E Evoy
The Annals of Pharmacotherapy|May 10, 2013
Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edemaKirk E Evoy, Steven R Abel
Journal of the American College of Clinical Pharmacy : JACCP|April 20, 2026
Embracing Pharmacists' Opportunities to Improve Care for People Living With Substance Use DisordersKirk E Evoy, Paul M Stranges
The Annals of Pharmacotherapy|May 16, 2013
Aflibercept: newly approved for the treatment of macular edema following central retinal vein occlusionKirk E Evoy, Steven R Abel
The American Journal of Drug and Alcohol Abuse|January 27, 2016
Combination bupropion SR and varenicline for smoking cessation: a systematic reviewTiffany Vogeler, Claire McClain, Kirk E Evoy
Current Psychiatry Reports|August 5, 2025
The Impact of Diverse Kratom Products on Use Patterns, Dependence, and ToxicityNina Vadiei, Kirk E Evoy, Oliver Grundmann
JAMA Internal Medicine|October 8, 2019
State-Level Approaches to Expanding Pharmacists' Authority to Dispense Naloxone May Affect AccessibilityLucas G Hill, Kelly R Reveles, Kirk E Evoy
Integrated Pharmacy Research & Practice|February 24, 2021
Considering the Potential Benefits of Over-the-Counter NaloxoneKirk E Evoy, Lucas G Hill, Corey S Davis
Integrated Pharmacy Research & Practice|July 16, 2021
Reply to Letter to the Editor Regarding Article: "Considering the Potential Benefits of Over-The-Counter Naloxone" [Response To Letter]Kirk E Evoy, Lucas G Hill, Corey S Davis
The Annals of Pharmacotherapy|February 11, 2015
Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomniaKunal V Patel, Anthony V Aspesi, Kirk E Evoy
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Frontiers in Public Health|September 4, 2024
Editorial: Reviews in opioid use disordersWendy Walwyn, Kirk E Evoy
The Annals of Pharmacotherapy|May 10, 2013
Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edemaKirk E Evoy, Steven R Abel
Journal of the American College of Clinical Pharmacy : JACCP|April 20, 2026
Embracing Pharmacists' Opportunities to Improve Care for People Living With Substance Use DisordersKirk E Evoy, Paul M Stranges
The Annals of Pharmacotherapy|May 16, 2013
Aflibercept: newly approved for the treatment of macular edema following central retinal vein occlusionKirk E Evoy, Steven R Abel
The American Journal of Drug and Alcohol Abuse|January 27, 2016
Combination bupropion SR and varenicline for smoking cessation: a systematic reviewTiffany Vogeler, Claire McClain, Kirk E Evoy
Current Psychiatry Reports|August 5, 2025
The Impact of Diverse Kratom Products on Use Patterns, Dependence, and ToxicityNina Vadiei, Kirk E Evoy, Oliver Grundmann
JAMA Internal Medicine|October 8, 2019
State-Level Approaches to Expanding Pharmacists' Authority to Dispense Naloxone May Affect AccessibilityLucas G Hill, Kelly R Reveles, Kirk E Evoy
Integrated Pharmacy Research & Practice|February 24, 2021
Considering the Potential Benefits of Over-the-Counter NaloxoneKirk E Evoy, Lucas G Hill, Corey S Davis
Integrated Pharmacy Research & Practice|July 16, 2021
Reply to Letter to the Editor Regarding Article: "Considering the Potential Benefits of Over-The-Counter Naloxone" [Response To Letter]Kirk E Evoy, Lucas G Hill, Corey S Davis
The Annals of Pharmacotherapy|February 11, 2015
Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomniaKunal V Patel, Anthony V Aspesi, Kirk E Evoy
Pageof 6